Bydureon Cancer

The risk for Bydureon cancer is a real concern for patients taking the type 2 diabetes drug. Proven in animal studies to cause thyroid cancer, the exenatide extended-release drug is now under investigation by the U.S. Food and Drug Administration (FDA) for possible increased risk of pancreatic cancer.

If you developed thyroid or pancreatic cancer after taking Bydureon, investigate your potential claim against the drugmaker by talking with an experienced products liability lawyer.

What is Bydureon?

Marketed as the “next generation of exenatide,” Bydureon is the first type 2 diabetes treatment providing a continuous supply of exenatide through one weekly injection. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, mimics incretin hormones the body usually produces naturally after ingestion of a meal. Type 2 adult diabetics are prescribed exenatide drugs under the names Bydureon and Byetta to improve glycemic control.

After declined twice by the FDA, Amylin Pharmaceuticals finally won approval for Bydureon in 2012. According to a report by the New York Times, analysts initially expected annual sales exceeding $1 billion, but lost some enthusiasm due to concerns about thyroid cancer and pancreatitis.

Bydureon Cancer Risks

Bydureon product safety information includes a black box warning stating that the exenatide extended-release drug causes thyroid C-cell at “clinically relevant exposures” in rats. According to the cancer warning, is not known if Bydureon causes thyroid cancer in people, but patients with a personal or family history of thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (heredity cancer syndrome associated with tumors of the endocrine system) should not take the drug. The safety information also says patients prescribed the drug should tell their physician if symptoms of thyroid cancer develop.

Exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Some diabetics with acute pancreatitis develop pancreatic cancer.

The FDA is investigating reports of increased pancreatic cancer risk in patients taking Bydureon or Byetta. According to the FDA, findings by a group of academic researchers suggest pre-cancerous cellular changes may be associated with incretin mimetics. Bydureon and Byetta are among drugs in the incretin mimetic class.

Bydureon Cancer Lawyer

If you are seeking a Bydureon cancer lawyer, you or a family member were probably diagnosed with thyroid or pancreatic cancer after taking the type 2 diabetes drug. If so, you need a law firm with the resources and experience it takes to bring such a claim against a large pharmaceutical company. You need Watts Guerra LLP.

Mikal Watts is one of the country’s most successful pharmaceutical lawyers. Watts and Mass Torts department Managing Partner Ryan L. Thompson are currently handling the largest incretins pancreatic cancer injury and wrongful death docket in the U.S. The firm is still accepting cases involving thyroid or pancreatic cancer associated with one of the type 2 diabetes drug, and provides free case evaluations. Let these experienced lawyers help you prove your Bydureon cancer case.  

Disclaimer: The images on this page of the Byetta packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Amylin Pharmaceuticals Inc.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.

Ryan L. Thompson

Ryan L. Thompson Ryan L. Thompson leads the firm's pharmaceutical and medical device litigation department. He serves as the firm's lead counsel for Actos, NuvaRing, DePuy Hips, Transvaginal Mesh, and other torts. Additionally, Ryan was appointed to serve as Co-Lead counsel nationally in the Incretin-Based Therapies MDL by US District Judge Anthony Battaglia for plaintiff's claiming injuries related to Byetta, Januvia, Janumet, and Victoza.
Contact us using our online form, or call us toll-free at 1(800)796-9605.